[14C] and [3H]-labelling of Ragaglitazar: A dual acting PPARα and PPARγ agonist with hypolipidemic and anti-diabetic activity
Currently, Ragaglitazar is being developed as a drug for the treatment of hyperglycaemia and hyperlipidemia in patients with type 2 diabetes. Here, we report the labelling of Ragaglitazar with carbon-14 and tritium for in vivo and in vitro investigations.
Kristensen, Jesper B.,Johansen, Steen K.,Valsborg, Jacob S.,Martiny, Lars,Foged, Christian